Published by
Reuters UK
Reuters UK
(Reuters) -Pfizer Inc is in advanced talks to buy drugmaker Global Blood Therapeutics for about $5 billion, the Wall Street Journal reported on Friday, citing people familiar with the matter. Pfizer is aiming to seal a deal in the coming days, but other suitors are still in the mix, the report said. Shares of Global Blood, which makes a blood disorder drug called Oxbryta, soared 44% in afternoon trade to a two-year high. The company had a market capitalization of $3.12 billion, as of Thursday’s closing price. Pfizer declined to comment on the report, while a Global Blood spokesperson said it d…
Share this Story
